This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.
Age greater than or equal to18 years old;
Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1;
Life expectancy >3 months;
Histologically confirmed B-cell B-cell non-Hodgkin's lymphoma;
Received autologous stem cell transplantation within 12 weeks before the first study treatment; previously received allogeneic stem cell transplantation; received Car-T cell therapy within 12 weeks before the first study treatment;
History of recent major surgery or severe trauma within 4 weeks before the first study treatment;
Received anti-tumour treatment within 2 weeks before the first study treatment;
Central nervous system (CNS) infiltration;